Solventum (NYSE:SOLV - Get Free Report) is anticipated to release its earnings data after the market closes on Thursday, February 27th. Analysts expect Solventum to post earnings of $1.31 per share and revenue of $2.05 billion for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Solventum Stock Performance
Solventum stock traded down $1.42 during trading hours on Friday, reaching $73.08. The company had a trading volume of 570,685 shares, compared to its average volume of 724,631. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a 50-day moving average price of $71.14 and a 200 day moving average price of $69.07.
Analysts Set New Price Targets
A number of equities research analysts recently commented on SOLV shares. Piper Sandler upped their price target on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a report on Friday, November 8th. Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Mizuho initiated coverage on Solventum in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Solventum presently has an average rating of "Hold" and a consensus price target of $68.29.
Check Out Our Latest Stock Report on Solventum
Solventum Company Profile
(
Get Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
